I am not sure what you mean by "there is one jumping out". 

If my understanding is correct, an important condition for a BTD from the FDA is that the research is presented in a conference and published.  That way, the FDA can solicit independent opinion from relevant experts, as part of the FDA's due diligence.  So not presenting at this conference has to be a negative.  I am of course happy to be corrected on this issue.